Randomised controlled trial to compare the efficacy of tablet Minoxidil 1.25mg Vs tablet minoxidil 2.5mg Vs topical 5% minoxidil solution in Male Pattern Hair Loss.
Phase 4
- Conditions
- Health Condition 1: L649- Androgenic alopecia, unspecified
- Registration Number
- CTRI/2022/12/048560
- Lead Sponsor
- Bhumika Mahawar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Male patients of age group 20-45 years clinically diagnosed with androgenetic alopecia of all grades
Male patients who are willing to participate in the study and gave consent for intake of oral minoxidil in 1.25 mg and 2.5 mg doses
Exclusion Criteria
1. Patients whose BP is lower than 100/60 mmHg.
2.Patients who have taken treatment for androgenetic alopecia in the previous 3 months.
3. Patients who are on other medications that reduce the blood pressure.
4.Patients diagnosed with pheochromocytoma, pulmonary hypertension, severe hepatic dysfunction, angina or recent myocardial infarction.
5.Patients having hypersensitivity to minoxidil.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method